Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension (REPAIR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02310672
Recruitment Status : Active, not recruiting
First Posted : December 8, 2014
Last Update Posted : March 7, 2019
Sponsor:
Information provided by (Responsible Party):
Actelion

Brief Summary:
The study evaluates the effect of macitentan on right ventricular and hemodynamic properties in patients with symptomatic pulmonary arterial hypertension. Patients are treated with macitentan for 1 year. Patients undergo right heart catheterization (RHC) at baseline and Week 26. They also undergo cardiac magnetic resonance imaging (MRI) at baseline, Week 26 and Week 52. Safety is monitored throughout the study. The study has three stub-studies. Each patient can participate in no sub-study or in one sub-study. The sub-studies are: (1) metabolism sub-study (with PET-MR scans); (2) biopsy sub-study (biopsies taken during the RHC); (3) Echo sub-study.

Condition or disease Intervention/treatment Phase
Pulmonary Arterial Hypertension Drug: Macitentan Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 89 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Effects of Macitentan on Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension Assessed by Cardiac Magnetic Resonance Imaging
Actual Study Start Date : June 1, 2015
Estimated Primary Completion Date : September 1, 2019
Estimated Study Completion Date : September 1, 2019


Arm Intervention/treatment
Experimental: Macitentan
All patients take open-label macitentan 10mg o.d.
Drug: Macitentan
All patients take open-label macitentan 10mg o.d.
Other Name: ACT-064992




Primary Outcome Measures :
  1. To evaluate the effect of macitentan on right ventricular and hemodynamic properties in patients with symptomatic pulmonary arterial hypertension (PAH). [ Time Frame: Baseline to Week 26 ]
    Change in Right Ventricular Stroke Volume and ratio of Week 26 to baseline PVR


Secondary Outcome Measures :
  1. To investigate the effect of macitentan on ventriculo-arterial coupling in patients with symptomatic PAH. [ Time Frame: baseline to Week 26 ]
    Change in arterial elastance

  2. To evaluate the safety and tolerability of macitentan in patients with symptomatic PAH. [ Time Frame: Base line to 30 days after End of Treatment (Week 52) ]
    Treatment-emergent adverse events (AEs) up to 30 days after EOT.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed informed consent prior to any study-mandated procedure
  2. Symptomatic pulmonary arterial hypertension (PAH)
  3. World Health Organization (WHO) Functional Class (FC) I to III
  4. PAH etiology belonging to one of the following groups according to Nice classification:

    • Idiopathic PAH
    • Heritable PAH
    • Drug- and toxin-induced PAH
    • PAH associated with congenital heart diseases: only simple (atrial septal defect, ventricular septal defect, patent ductus arteriosus) congenital systemic to pulmonary shunts at least 2 year post surgical repair
  5. Hemodynamic diagnosis of PAH confirmed by right heart catheterization (RHC) during screening showing:

    • mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and

    • PCWP (pulmonary capillary wedge pressure) or left ventricular end diastolic pressure (LVEDP) ≤ 12 mmHg and pulmonary vascular resistance (PVR) ≥ 4 Wood Units (WU) (320 dyn.sec.cm-5) or
    • 12 mmHg ≤ PCWP or LVEDP ≤ 15 mmHg and PVR ≥ 6WU (480 dyn.sec.cm-5)
  6. 6-minute walk distance (6MWD) ≥ 150 m during screening
  7. For patients treated with oral diuretics, treatment dose must have been stable at least 1 month prior to RHC during the screening period
  8. For patients treated with phosphodiesterase type-5 (PDE-5) inhibitors, treatment dose must have been stable at least 3 months prior to RHC during the screening period
  9. For patients treated with beta blockers, treatment dose must have been stable at least 1 month prior to the RHC during the screening period
  10. Men or women ≥18 and < 65 years
  11. Women of childbearing potential (defined in protocol) must:

    • Have a negative serum pregnancy test during screening and a negative urine pregnancy test on Day 1, and
    • Agree to use reliable methods of contraception (defined in protocol) from screening up to 30 days after study treatment discontinuation, and
    • Agree to perform monthly pregnancy tests up to 30 days after study treatment discontinuation

Exclusion Criteria:

  1. Body weight < 40 kg
  2. Body mass index (BMI) > 35kg/m2. For patients with 30kg/m2 < BMI < 35kg/m2, an eligibility form will be submitted to a Steering Committee member who will reserve the right to exclude the patient.
  3. Pregnancy, breastfeeding or intention to become pregnant during the study
  4. Recently started (< 8 weeks prior to informed consent signature) or planned cardio-pulmonary rehabilitation program
  5. Known concomitant life-threatening disease with a life expectancy < 12 months
  6. Any condition likely to affect protocol or treatment compliance
  7. Hospitalization for PAH within 3 months prior to informed consent signature
  8. Left atrial volume indexed for body surface area ≥ 43mL/m2 by echocardiography or cardiac MRI
  9. Valvular disease grade 2 or higher
  10. History of pulmonary embolism or deep vein thrombosis
  11. Documented moderate to severe chronic obstructive pulmonary disease
  12. Documented moderate to severe restrictive lung disease
  13. Historical evidence of significant coronary artery disease established by:

    • History of myocardial infarction or
    • More than 50% stenosis in a coronary artery (by percutaneous coronary intervention or angiography) or
    • Elevation of the ST segment on electrocardiogram or
    • History of coronary artery bypass grafting or
    • Stable angina
  14. Diabetes mellitus
  15. Moderate to severe renal insufficiency (calculated creatinine clearance < 60 mL/min/1.73 m2)
  16. Cancer
  17. Systolic blood pressure < 90 mmHg
  18. Severe hepatic impairment (with or without cirrhosis) according to National Cancer Institute organ dysfunction working group criteria, defined as total bilirubin > 3 × upper limit of the normal range (ULN) accompanied by an aspartate aminotransferase (AST) elevation > ULN at Screening.
  19. Hemoglobin < 100g/L
  20. AST and/or alanine aminotransferase (ALT) > 3× ULN
  21. Need for dialysis
  22. Responders to acute vasoreactivity test based on medical history
  23. Prior use of endothelin receptor antagonists (ERAs), stimulators of soluble guanylate cyclase or prostacyclin or prostacyclin analogues
  24. Treatment with strong inducers of cytochrome P450 isozyme 3A4 (CYP3A4) within 4 weeks prior to study treatment initiation (e.g., carbamazepine, rifampicin, rifabutin, phenytoin and St. John's Wort)
  25. Treatment with strong inhibitors of CYP3A4 within 4 weeks prior to study treatment initiation (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir)
  26. Treatment with another investigational drug (planned, or taken within the 3 months prior to study treatment initiation).
  27. Hypersensitivity to any ERA or any excipients of the formulation of macitentan (lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate, polyvinyl alcohol, polysorbate, titanium dioxide, talc, xanthan gum, and lecithin soya)
  28. Claustrophobia
  29. Permanent cardiac pacemaker, automatic internal cardioverter
  30. Metallic implant (e.g., defibrillator, neurostimulator, hearing aid, permanent use of infusion device)
  31. Atrial fibrillation, multiple premature ventricular or atrial contractions, or any other condition that would interfere with proper cardiac gating during MRI.
  32. For patients enrolling in the metabolism sub-study only: glucose intolerance
  33. For patients enrolling in the biopsy sub-study only: PAH etiology belonging to Nice classification 1.4.4: PAH associated with congenital heart diseases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02310672


  Show 41 Study Locations
Sponsors and Collaborators
Actelion
Investigators
Layout table for investigator information
Study Director: Loïc Perchenet Actelion

Layout table for additonal information
Responsible Party: Actelion
ClinicalTrials.gov Identifier: NCT02310672     History of Changes
Other Study ID Numbers: AC-055-403
First Posted: December 8, 2014    Key Record Dates
Last Update Posted: March 7, 2019
Last Verified: March 2019

Keywords provided by Actelion:
Pulmonary Arterial Hypertension

Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Familial Primary Pulmonary Hypertension
Ventricular Remodeling
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases
Pathological Conditions, Anatomical
Macitentan
Endothelin A Receptor Antagonists
Endothelin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Endothelin B Receptor Antagonists